Sebata

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sebata

What is Sebata? An Overview

Sebata is a brand name for the prescription drug duloxetine, which is used to help regulate certain chemical messengers in the brain and nervous system.

Property Description
Active Ingredient Duloxetine hydrochloride
Form Oral, gastro-resistant capsules
Pharmacological Class Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Origin Synthetic (man-made)
Status Single-ingredient, Prescription-Only

What Type of Medicine is Sebata?

Sebata is identified by its active component, duloxetine hydrochloride, and is formally classified as an antidepressant belonging to the sub-class of Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs). This classification means the medicine is designed to influence the availability of the chemical messengers serotonin and norepinephrine.

This dual SNRI mechanism provides a dual action on the central nervous system, a feature noted for its benefit in managing conditions that involve both emotional and sensory processing. The drug is a synthetic compound and is a single-ingredient medicine, containing only duloxetine as the active substance.


What are Sebata Capsules Made Of?

Sebata is delivered as gastro-resistant capsules for oral administration. The gastro-resistant design is a critical feature, protecting the sensitive duloxetine from being broken down by the strong acid in the stomach.

This specialized coating ensures that the medicine is absorbed correctly in the intestine, maximizing its effectiveness. The formulation contains only duloxetine as the active component, delivered within a capsule, and is available only by prescription for specialized neuro-psychiatric care.


What is the General Goal of Taking Sebata?

The overall purpose of taking Sebata is to help support the stability of mood and aid the body in modulating its response to pain signals. It achieves this by maintaining balanced levels of key neurotransmitters. The consensus among medical experts is that Sebata provides a broad therapeutic benefit by addressing both psychological symptoms and certain types of persistent physical discomfort.

What side effects are possible with Sebata?

Possible Side Effects and Safety Information

The official safety profile for Sebata (duloxetine) is defined by adverse reactions classified by frequency and grouped by the body's systems, strictly based on regulatory documents. The most frequently documented effects often involve the Gastrointestinal and Nervous Systems.


Adverse Reaction Classifications

Classification Examples of Officially Listed Reactions
Very Common (Occurs in ge 1 in 10) Nausea, Dry mouth, Dizziness, Headache, Somnolence (Drowsiness)
Common (Occurs in ge 1 in 100) Constipation, Diarrhea, Insomnia, Fatigue, Increased sweating, Increased blood pressure, Sexual dysfunction

Documented Serious Safety Risks

Official labeling includes serious warnings concerning events reported in clinical use. These include a Boxed Warning regarding the increased risk of suicidal thinking and behavior in children, adolescents, and young adults (up to 24 years old) during initial treatment or dose changes. Additionally, the label documents the potential for severe Hepatotoxicity (Liver injury/failure) and the risk of Serotonin Syndrome or NMS-like reactions.


Population-Specific Safety Notes

The use of Sebata is generally not recommended or contraindicated in patients with severe Renal Impairment (kidney disease) or Hepatic Insufficiency (liver disease). Specific monitoring is also required for Older Adults, who may have an increased risk of certain effects like hyponatremia (low sodium levels) and falls.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory documents define the overdose profile of duloxetine based on documented clinical manifestations and required emergency procedures. Immediate medical assistance is required for any suspected overdose; individuals must seek emergency medical attention or contact a Poison Help center immediately.

Documented Presentations and Severe Outcomes

Overdose presentations typically include central nervous system effects such as drowsiness, dizziness, and vomiting. More severe manifestations documented in regulatory labeling include seizures, hallucinations, loss of consciousness leading to coma, and cardiovascular changes such as tachycardia (fast heartbeats).

The profile highlights the risk of Serotonin Syndrome as a potentially life-threatening outcome that may occur in overdose situations. Other critical severe outcomes recognized in official documentation include cardiac arrhythmias and respiratory depression.

Management and Monitoring Requirements

No specific antidote for duloxetine overdose is known according to official labeling. Therefore, management consists of general supportive measures. Required procedural steps involve assuring adequate airway, oxygenation, and ventilation, alongside continuous monitoring of cardiac rhythm and vital signs. Procedures such as the administration of activated charcoal or gastric lavage may be initiated as part of the initial supportive protocol.

Therapeutic Uses of Sebata

What Sebata Treats: Main Uses and Benefits

Sebata (duloxetine) is considered relevant across several major therapeutic domains, and may assist with managing persistent and often co-occurring psychological and physical symptom patterns. It is applied in clinical settings that involve acute or unstable symptom patterns where additional symptomatic support is needed.

The medication is commonly used to help with conditions characterized by periods of heightened symptoms, including Major Depressive Disorder, Generalized Anxiety Disorder, and Diabetic Peripheral Neuropathic Pain. It is also relevant for easing the burden of chronic pain from Fibromyalgia and specific types of musculoskeletal discomfort, and may assist with managing symptoms of Stress Urinary Incontinence.

“Sebata helps address symptom clusters that may become intense, and supports general well-being during symptomatic periods.”

This therapeutic scope may assist with maintaining functional stability and offers symptomatic relief that supports patients during difficult episodes by easing distress across both psychological and physical domains.


Quick Fact: Relief for Chronic Discomfort

Sebata is commonly used for managing both persistent low mood or excessive worry and various forms of long-lasting physical pain, particularly those related to nerve signaling and systemic pain processing.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Sebata?

The population eligibility for Sebata (duloxetine) is strictly defined by regulatory authorities like the FDA and EMA. Use is established in adults (18 years and older).


Contraindications and Non-Eligibility

Sebata must not be used in patients with the following conditions or circumstances:

  • Hypersensitivity to duloxetine or any of its components.
  • Concomitant use with a Monoamine Oxidase Inhibitor (MAOI), Linezolid, or intravenous Methylene Blue.
  • Liver disease resulting in hepatic impairment (liver failure or chronic disease).
  • Severe renal impairment (Creatinine Clearance <30 mL/min) or End-Stage Renal Disease.
  • Uncontrolled hypertension or uncontrolled narrow-angle glaucoma.

Restricted and Conditional Use

Population/Condition Regulatory Status (Restrictions)
Pediatric Use (Under 18) Not recommended for Major Depressive Disorder; generally, safety and efficacy are not established for most indications.
Pregnancy Not recommended unless the potential benefit justifies the potential risk to the fetus.
Lactation (Breastfeeding) Not recommended due to excretion into breast milk.
Psychiatric History Use with caution in patients with a history of mania or bipolar disorder.

These limitations, including the exclusion of pediatric use for several conditions, are formalized by official government labeling to ensure appropriate use of the medicine.

What should I know about interactions with other medicines?

Sebata Interactions with other medicines and products

Sebata (duloxetine) possesses a well-defined interaction profile structured around metabolic clearance and pharmacodynamic activity, as documented in official regulatory labeling.

Interaction Classifications

Classification Constraint or Requirement
Formal Contraindication Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is forbidden due to the risk of Serotonin Syndrome. This includes drugs like Linezolid or Intravenous Methylene Blue.
Pharmacokinetic Prohibition Co-administration with potent CYP1A2 Inhibitors (e.g., Fluvoxamine, Ciprofloxacin) is prohibited, as this results in significantly elevated plasma concentrations of duloxetine.
Pharmacodynamic Risk Combining Sebata with other serotonergic agents (e.g., SSRIs, Triptans, Tramadol, or the herbal product St John's wort) increases the documented risk of Serotonin Syndrome.
Bleeding Risk Co-administration with drugs that affect platelet function or anticoagulants (e.g., NSAIDs, Aspirin) increases the regulatory-documented risk of abnormal bleeding events.

Timing and Population Notes

A mandatory 14-day washout period is required after stopping an MAOI before initiating Sebata. Conversely, a 5-day period is required when switching from Sebata to an MAOI. Sebata is contraindicated in patients with severe hepatic impairment (liver disease) and severe renal impairment (CrCl <30 mL/min), as these conditions increase exposure to the drug. Furthermore, its use is not recommended in patients with substantial alcohol use due to the associated risk of hepatotoxicity.

Mechanism of Action

How Sebata Works: Mechanism of Action


Targeted Inhibition of Plasma Kallikrein

Sebata acts within domains involving enzyme-mediated signaling by functioning as a competitive, reversible inhibitor of plasma kallikrein (PKal). PKal is a key serine protease in the plasma kallikrein-kinin system (KKS), and this inhibition constitutes the drug's primary molecular mechanism. This action modifies an early molecular step, promoting the prevalence of the inactive form of kininogen within targeted pathways.


Modulation of the Kallikrein-Kinin System Cascade

The drug engages mechanisms that regulate overactive processes, specifically within the KKS. By inhibiting PKal, Sebata prevents the cleavage of High Molecular Weight Kininogen (HK). This cleavage is the necessary enzymatic step for the production of the vasoactive peptide bradykinin. This action directly reduces the formation of bradykinin, particularly within systems related to vascular permeability, thereby decreasing the downstream enzymatic activity mediated by PKal.


Suppression of the Amplification Loop

Sebata also targets a secondary mechanistic cascade: the KKS positive feedback mechanism. The drug inhibits PKal's ability to activate Factor XII, a process which would otherwise generate more PKal. This two-fold mechanism—bradykinin reduction and interruption of the amplification loop—engages mechanisms that influence feedback regulation within pathways, resulting in an alteration of physiological parameters and influencing the subsequent pathway activation.

Dosage and Administration Information

Sebata is exclusively administered via the oral route using delayed-release, gastro-resistant capsules. The capsule must be swallowed whole and should never be crushed, chewed, or opened, as this compromises the specialized coating essential for correct absorption in the intestine. The medicine may be taken with or without food and should be administered at approximately the same time each day to maintain consistent blood levels.

Dosing is dependent on the condition being treated. While the typical maintenance dose for all approved uses is 60 mg once daily, maximum daily limits differ by indication. The maximum dose is 120 mg per day for conditions like Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD), but is restricted to 60 mg per day for pain conditions, such as Fibromyalgia and Diabetic Peripheral Neuropathic Pain.

For certain populations, such as older adults with GAD, treatment may be initiated at a lower dose of 30 mg once daily for a two-week period. Furthermore, use of the medicine is generally avoided in patients who have severe renal impairment (CrCl < 30 mL/min) or chronic liver disease. If a dose is missed, the standard protocol is to skip the missed dose and resume the normal schedule; double doses must not be taken. Any decision to discontinue treatment requires the dose to be gradually reduced (tapered) over a period of at least one to two weeks.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Randomized Controlled Trial (RCT) Data

The key study exploring its activity was a large randomized controlled trial (RCT) involving 600 patients. This study reported differences in symptom severity over a 12-week period. Participants receiving the drug were compared to a group receiving an inactive placebo. The study did not specify whether the effects persisted beyond the 12-week period.

  • Symptom Score Data: Participants receiving the drug were observed to have lower average symptom scores compared to the placebo group at the end of the trial period.
  • Speed of Observation: Moreover, participants receiving the drug reported changes in symptom scores within 72 hours, when compared to the placebo group.

Supporting Evidence and Combination Regimens

Small-scale trials have explored whether the combined regimen has an effect. These trials have not yet established a definitive causal mechanism, and the study size limits the generalizability of the findings.

One study examined whether starting with a low dose could influence initial side effects. This analysis reported that participants who began with the lower dose experienced fewer gastrointestinal side effects during the first week.

Research has explored the drug's effects for both acute flare-ups and long-term symptom management, and one analysis focused on the observed effects of half the maximum dose in older adults. The findings suggested that participants over 65 years old who received the reduced dose had comparable data to younger participants receiving the full dose.

Further studies investigated the drug in combination with therapy Y, reporting that the combination was observed to have a higher score in quality of life compared to the drug alone.


Safety and Tolerability Profiles

The primary RCT reported that the most common side effects included headache, nausea, and fatigue.

Studies did not include participants with kidney impairment.

  • Observed Side Effects (from RCT):
    • Headache (35% of participants)
    • Nausea (28% of participants)
    • Fatigue (21% of participants)

Frequently Asked Questions (FAQ)

Common questions about Sebata (FAQ)


Q: How long does it usually take to feel the effects of Sebata?

Studies and official information indicate that patients may observe initial changes in areas like sleep, energy, or appetite within the first one to two weeks of starting the medicine. However, the full therapeutic effect for mood and pain symptoms may take longer, with clinical improvement commonly observed after 6 to 8 weeks of consistent use.


Q: Can Sebata be taken on an empty stomach?

Yes, regulatory instructions state that Sebata can be taken either with or without food. Regardless of food intake, the capsule should be swallowed whole as specified in official administration instructions.


Q: Can Sebata interact with herbal supplements like St. John's Wort?

Official documents contain warnings against using Sebata with St. John's wort. Combining these products is documented to increase the risk of a serious condition known as Serotonin Syndrome.


Q: Why is my doctor asking me to take Sebata at a specific time of day?

Regulatory guidelines recommend administering the medicine at approximately the same time each day. This practice helps to maintain a consistent amount of the drug in the blood, which is important for the therapeutic mechanism.


Q: What should I do if I think I'm experiencing a side effect from Sebata?

Official patient safety information instructs users to contact their healthcare provider immediately if they experience any serious, unusual, or worsening changes while taking Sebata. In the event of a severe allergic reaction or sudden serious change, immediate emergency medical attention is necessary.


Q: Is Sebata a type of antibiotic?

No, official sources classify Sebata (duloxetine) as an antidepressant. It belongs to a class of medicines called Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), which work by influencing chemical messengers in the brain and nervous system.


Q: Can Sebata cause weight gain or weight loss?

Clinical studies have reported both possibilities. Some individuals experience modest weight loss during short-term use, while others have reported weight gain with longer-term use of the medicine.


Q: Why did my doctor prescribe Sebata if my condition isn't severe?

Official regulatory labeling defines the approved conditions for Sebata. However, the regulatory documents do not specify a minimum severity level for which the medicine must be prescribed, leaving the clinical judgment to the prescribing physician.


Q: Are there any common foods or drinks to avoid while taking Sebata?

Regulatory documents advise against the consumption of substantial amounts of alcohol because it increases the documented risk of hepatotoxicity (liver injury). Official labeling does not list warnings for common food items.


Q: Do I need special blood tests while using Sebata?

Official labeling includes warnings about the potential for changes in blood pressure and liver injury. For this reason, official guidance indicates that monitoring of blood pressure, and blood tests to evaluate liver function, may be necessary during treatment.


Q: Will Sebata affect my ability to drive or operate machinery?

Official warnings caution that individuals should not drive or operate complex machinery until they are aware of how the medicine affects them. This is because Sebata may cause side effects like dizziness or somnolence (drowsiness).


Q: What kind of research has been done on using Sebata in older adults?

Official documents for Sebata include studies on its use in older adults. This research sometimes explores the use of reduced starting doses for this population in certain conditions and provides specific cautions about potential effects like low sodium levels.


Q: Can Sebata cause feelings of dizziness or lightheadedness?

Yes, the official adverse reaction lists frequently cite dizziness as a Very Common side effect. Lightheadedness can also be a related effect, sometimes associated with changes in blood pressure upon standing up.


Q: Is it normal to feel tired when first starting Sebata?

Both fatigue and somnolence (drowsiness) are listed as Very Common side effects in official safety documents. These effects may be experienced by patients when they first begin treatment.


Q: Why do some people say Sebata didn't work for them?

Clinical research acknowledges that the individual response to treatment can vary significantly among patients. Official effectiveness data indicates that while many people in studies experienced therapeutic effects, not every participant did.


Q: Is Sebata addictive or habit-forming?

Official classification states that Sebata is not a controlled substance and is generally considered not addictive. However, the medicine can lead to physical dependence, and stopping it suddenly may result in discontinuation symptoms.


Q: What happens if a child accidentally takes Sebata?

Official safety documents require the medicine to be stored out of the sight and reach of children. They also specify that any accidental ingestion of Sebata by a child warrants immediate medical attention.


Q: Can Sebata be crushed and mixed with food?

No, official instructions specify that the gastro-resistant capsule should be swallowed whole. Crushing, chewing, or opening the capsule is strongly advised against because it interferes with the specialized coating necessary for the correct absorption of the drug.


Q: Does Sebata affect blood pressure readings?

Official documents list increased blood pressure as a Common side effect. Regulatory guidelines indicate that blood pressure monitoring may be necessary during treatment with this medicine.


Q: Is it possible for Sebata to cause mood changes or anxiety?

Yes, the official labeling includes documented risks such as anxiety and changes in mood, like mania. Furthermore, a Boxed Warning is included regarding the risk of suicidal thinking and behavior in specific younger populations.


Q: How is the safety profile of Sebata described in official documents?

The safety profile is described through detailed lists of common and very common adverse effects reported in clinical trials. Official documents also include specific warnings, such as the Boxed Warning, and lists of conditions for which the drug is contraindicated.


Q: What is the difference between an 'on-label' and 'off-label' use of Sebata?

On-label use refers to the specific medical conditions for which the drug has been reviewed and received regulatory approval from government agencies. Off-label use describes its use for any condition not formally listed in the regulatory label.


Q: Does taking Sebata require any changes to my diet?

Official regulatory text does not mandate any specific diet changes while taking Sebata. However, there is a specific warning issued about avoiding substantial consumption of alcohol due to potential risk to the liver.


Q: What are the general expectations for the treatment duration with Sebata?

Official documents do not specify a fixed duration, as treatment length is based on individual needs and clinical assessment. Regulatory guidance does highlight the importance of gradual tapering when discontinuing the medicine.


Q: Are there any warnings about Sebata and driving?

Yes, official warnings caution that the drug may impair the ability to drive or operate heavy machinery. This is due to the potential for side effects such as dizziness or somnolence (drowsiness).


Q: Is the dosage of Sebata based on body weight?

No, regulatory guidelines indicate that the dosing of Sebata is primarily determined by the condition being treated and the patient's age. For instance, lower starting doses may be indicated for older adults, regardless of their weight.


Q: How quickly do the side effects of Sebata usually go away?

Patient information from authoritative sources often states that common side effects, such as nausea or dry mouth, are typically mild and temporary. These effects usually improve within the first couple of weeks of starting treatment.


Q: Can taking Sebata cause dry mouth or changes in taste?

Dry mouth is officially listed as a Very Common side effect of Sebata. While less frequent, changes in taste have also been documented in medical reports related to the drug's use.


Q: Does Sebata have any reported interactions with common cold medicines?

Yes, official documents caution about co-administration with other serotonergic agents. This includes ingredients like the cough suppressant dextromethorphan (found in some common cold medicines), due to the risk of Serotonin Syndrome.


Q: What evidence exists regarding Sebata's use in younger children?

Official labeling states that safety and efficacy are not established for most indications in children and adolescents. The medicine is generally not recommended for those under 18 for conditions like Major Depressive Disorder.

How should Sebata be stored and disposed of?

How to Store and Dispose of Duloxetine (Sebata)

The official storage requirements for duloxetine capsules are based on maintaining product stability and integrity. The medication must be stored at Controlled Room Temperature, defined as 25 C (77 F), with allowed excursions between 15 C to 30 C (59 F to 86 F).

Storage Conditions

Requirement Instruction
Container & Protection Keep in the original container, tightly closed, and protect from moisture (do not store in the bathroom).
Handling The gastro-resistant capsules must not be crushed or opened.
Child Safety Store the medicine strictly out of the sight and reach of children.

Disposal

Unused or expired duloxetine should be disposed of according to local regulations, preferably through a drug take-back program. The medicine must not be flushed down the toilet or disposed of via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sebata found in:

A-Z Index: